What does in process research and development amount mean?

Reflects the capitalized value of research and development projects acquired through business combinations that have not yet reached technological feasibility. This metric is a primary indicator of the company's investment in future product pipelines and long-term growth potential.

Citius Oncology, Inc. CTOR In Process Research And Development Amount

In Process Research And Development Amount at other companies

SavaraSVRA

$11.36M+5.9%

RFL

Rafael Holdings, Inc.RFL

$31.58M0.0%

Aclaris TherapeuticsACRS

$21.73M+1,211%

UroGen PharmaURGN

$0-100%

Erasca, Inc.ERAS

$150M—

Harmony Biosciences Holdings, Inc.HRMY

$32M—

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-74.7%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept ctor:InProcessResearchAndDevelopmentAmount.

The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s in process research and development amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s in process research and development amount?: Citius Oncology, Inc. (CTOR) reported in process research and development amount of $18.35M in Q3 2025.
What does in process research and development amount mean?: Reflects the capitalized value of research and development projects acquired through business combinations that have not yet reached technological feasibility. This metric is a primary indicator of the company's investment in future product pipelines and long-term growth potential.